You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBevantolol
Accession NumberDB01295
TypeSmall Molecule
GroupsApproved
DescriptionBevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.
Structure
Thumb
Synonyms
(+-)-Bevantolol
1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol
1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol
1-(3,4-Dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol
1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol
Bevantololum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII34ZXW6ZV21
CAS number59170-23-9
WeightAverage: 345.4327
Monoisotopic: 345.194008357
Chemical FormulaC20H27NO4
InChI KeyHXLAFSUPPDYFEO-UHFFFAOYSA-N
InChI
InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
IUPAC Name
1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol
SMILES
COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1
Pharmacology
IndicationFor the treatment of angina pectoris and hypertension.
Structured Indications Not Available
PharmacodynamicsBevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.
Mechanism of actionAnimal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinunknown
antagonist
HumanP07550 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bevantolol Action PathwayDrug actionSMP00668
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bevantolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Experimental, Illicit
AceclofenacAceclofenac may decrease the antihypertensive activities of Bevantolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bevantolol.Approved
AcetohexamideBevantolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Bevantolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Acetylcholine.Approved
AcetyldigitoxinBevantolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bevantolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Experimental, Investigational
AlfentanilAlfentanil may increase the bradycardic activities of Bevantolol.Approved, Illicit
AlfuzosinBevantolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Bevantolol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Bevantolol.Approved, Investigational
AmobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Bevantolol can be decreased when combined with Amodiaquine.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Bevantolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bevantolol.Approved
AnvirzelBevantolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Arecoline.Experimental
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bevantolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bevantolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
BarbexacloneThe serum concentration of Bevantolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Barbital.Illicit
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bevantolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Illicit
BethanecholThe risk or severity of adverse effects can be increased when Bevantolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Bevantolol.Investigational
BL-1020BL-1020 may increase the hypotensive activities of Bevantolol.Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Bevantolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bevantolol.Investigational
BucindololBevantolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bevantolol.Approved, Investigational
CabergolineBevantolol may increase the vasoconstricting activities of Cabergoline.Approved
CarbacholThe risk or severity of adverse effects can be increased when Bevantolol is combined with Carbachol.Approved
CarprofenCarprofen may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved, Withdrawn
CarvedilolBevantolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bevantolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bevantolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
ChlorpropamideBevantolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bevantolol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Bevantolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bevantolol.Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bevantolol.Investigational
DapoxetineThe serum concentration of Bevantolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Bevantolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Bevantolol.Approved
DeslanosideBevantolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bevantolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Bevantolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Bevantolol.Approved
DigitoxinBevantolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinBevantolol may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Bevantolol.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bevantolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bevantolol.Approved
DonepezilDonepezil may increase the bradycardic activities of Bevantolol.Approved
DoxazosinBevantolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Bevantolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bevantolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
DuloxetineThe serum concentration of Bevantolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bevantolol.Investigational
E6201E6201 may decrease the antihypertensive activities of Bevantolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Bevantolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bevantolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bevantolol.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Bevantolol is combined with EPIBATIDINE.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bevantolol.Approved
Ergoloid mesylateBevantolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBevantolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bevantolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
EtoperidoneThe serum concentration of Bevantolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bevantolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Bevantolol.Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Bevantolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Bevantolol.Approved
FentanylFentanyl may increase the bradycardic activities of Bevantolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bevantolol.Vet Approved
FingolimodBevantolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bevantolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Bevantolol.Vet Approved
FluoxetineThe serum concentration of Bevantolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Bevantolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Bevantolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bevantolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bevantolol.Approved, Nutraceutical
GlibornurideBevantolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideBevantolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBevantolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBevantolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBevantolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideBevantolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideBevantolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bevantolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
HexobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Bevantolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Bevantolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bevantolol.Investigational
HydroxychloroquineThe metabolism of Bevantolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bevantolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bevantolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bevantolol.Approved
IndalpineThe serum concentration of Bevantolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndomethacinIndomethacin may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bevantolol.Withdrawn
IndoraminBevantolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkBevantolol may increase the hypoglycemic activities of Insulin Pork.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Bevantolol.Approved, Withdrawn
IsoxicamIsoxicam may decrease the antihypertensive activities of Bevantolol.Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Bevantolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bevantolol.Approved
LabetalolBevantolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
LevomilnacipranThe serum concentration of Bevantolol can be increased when it is combined with Levomilnacipran.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bevantolol.Approved, Vet Approved
LisofyllineLisofylline may decrease the antihypertensive activities of Bevantolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
LornoxicamLornoxicam may decrease the antihypertensive activities of Bevantolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bevantolol.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bevantolol.Approved
MalathionMalathion may increase the bradycardic activities of Bevantolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Bevantolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bevantolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Bevantolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bevantolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bevantolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bevantolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bevantolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Bevantolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bevantolol.Investigational
MethohexitalThe serum concentration of Bevantolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bevantolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bevantolol.Investigational
MethylphenobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Methylphenobarbital.Approved
MidodrineBevantolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Bevantolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Bevantolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Bevantolol.Investigational
MoricizineMoricizine may increase the hypotensive activities of Bevantolol.Approved, Withdrawn
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bevantolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Bevantolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bevantolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Bevantolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Bevantolol.Investigational
NefazodoneThe serum concentration of Bevantolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Bevantolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bevantolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Bevantolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Bevantolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bevantolol.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Bevantolol.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bevantolol.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Bevantolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bevantolol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bevantolol.Vet Approved
OuabainBevantolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bevantolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bevantolol.Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Bevantolol.Approved
ParoxetineThe serum concentration of Bevantolol can be increased when it is combined with Paroxetine.Approved, Investigational
PentobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Bevantolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Bevantolol.Approved
PhenobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Phenobarbital.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Bevantolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Bevantolol.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
PrazosinBevantolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Bevantolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Bevantolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bevantolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Bevantolol.Approved
PropafenoneThe serum concentration of Bevantolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bevantolol.Vet Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bevantolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bevantolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Bevantolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Bevantolol.Approved
ReserpineReserpine may increase the hypotensive activities of Bevantolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Bevantolol.Experimental, Investigational
RifampicinThe serum concentration of Bevantolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bevantolol can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Bevantolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bevantolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
SalicylamideSalicylamide may decrease the antihypertensive activities of Bevantolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bevantolol.Approved
SecobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
SertralineThe serum concentration of Bevantolol can be increased when it is combined with Sertraline.Approved
SilodosinBevantolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bevantolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Bevantolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bevantolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Bevantolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Bevantolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Bevantolol.Withdrawn
TamsulosinBevantolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Bevantolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bevantolol.Vet Approved
TerazosinBevantolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bevantolol.Approved
ThiamylalThe serum concentration of Bevantolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bevantolol.Withdrawn
ThiopentalThe serum concentration of Bevantolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Bevantolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bevantolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bevantolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
TolazamideBevantolol may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideBevantolol may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bevantolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Bevantolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
TrichlorfonTrichlorfon may increase the bradycardic activities of Bevantolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bevantolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
TrimazosinBevantolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Bevantolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Bevantolol.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bevantolol.Investigational, Withdrawn
VareniclineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Bevantolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Bevantolol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bevantolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bevantolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Bevantolol.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Yutaka Nomura, “Process for preparation of bevantolol hydrochloride.” U.S. Patent US5382689, issued December, 1974.

US5382689
General References
  1. Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. [PubMed:2888789 ]
External Links
ATC CodesC07AB06C07BB06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8271
Blood Brain Barrier-0.9297
Caco-2 permeable-0.6012
P-glycoprotein substrateSubstrate0.8119
P-glycoprotein inhibitor IInhibitor0.625
P-glycoprotein inhibitor IIInhibitor0.8061
Renal organic cation transporterNon-inhibitor0.6935
CYP450 2C9 substrateNon-substrate0.7741
CYP450 2D6 substrateSubstrate0.5792
CYP450 3A4 substrateSubstrate0.5727
CYP450 1A2 substrateNon-inhibitor0.6261
CYP450 2C9 inhibitorNon-inhibitor0.9068
CYP450 2D6 inhibitorNon-inhibitor0.7311
CYP450 2C19 inhibitorNon-inhibitor0.9218
CYP450 3A4 inhibitorNon-inhibitor0.6133
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9339
Ames testNon AMES toxic0.9124
CarcinogenicityNon-carcinogens0.926
BiodegradationNot ready biodegradable0.8696
Rat acute toxicity2.0966 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6187
hERG inhibition (predictor II)Inhibitor0.8681
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point137-138 °CPhysProp
logP3.00HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0137 mg/mLALOGPS
logP2.83ALOGPS
logP3.03ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area59.95 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity98.54 m3·mol-1ChemAxon
Polarizability39.75 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dimethoxybenzenes. These are organic aromatic compounds containing a monocyclic benzene moiety carrying exactly two methoxy groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassMethoxybenzenes
Direct ParentDimethoxybenzenes
Alternative Parents
Substituents
  • O-dimethoxybenzene
  • Dimethoxybenzene
  • Phenethylamine
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Toluene
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Hino T, Sakai K, Ichihara K, Abiko Y: Attenuation of ischaemia-induced regional myocardial acidosis by bevantolol, a beta 1-adrenoceptor antagonist, in dogs. Pharmacol Toxicol. 1989 Apr;64(4):324-8. [PubMed:2568629 ]
  2. Dukes ID, Vaughan Williams EM: Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. Br J Pharmacol. 1985 Feb;84(2):365-80. [PubMed:2858236 ]
  3. Lofdahl CG, Svedmyr K, Svedmyr N: Selectivity of bevantolol hydrochloride, a beta 1-adrenoceptor antagonist, in asthmatic patients. Pharmacotherapy. 1984 Jul-Aug;4(4):205-10. [PubMed:6148733 ]
  4. Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. [PubMed:2888789 ]
  5. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5. [PubMed:1358746 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 08:18 / Updated on August 17, 2016 12:23